BenzingaAugust 14, 2026 at 8:00 AM NY21 days ago

TD Cowen Maintains Buy on Ascendis Pharma, Raises Price Target to $341

TD Cowen analyst Yaron Werber maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and raises the price target from $325 to $341.

Read the Full Story at the Source

The summary here comes from the news provider; the rest of the article lives on the publisher's site — Benzinga

Companies in This Story